The Best of ASCO^® Miami Program Agenda

Faculty Disclosures

• Abstract #505: TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer. (J. Chang) 
• Abstract #509: LANDSCAPE: A FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole brain radiotherapy (WBR). (T. Bachelot)
• Abstract #506: Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to  neoadjuvant breast cancer chemotherapy. (F. Holmes)
• Abstract #LBA504: NCIC CTG MAP.3:  a phase III placebo-controlled Breast Cancer Prevention Trial of exemestane in postmenopausal women at risk for breast cancer. (P.E. Goss)
  
  Read ASCO Daily News Coverage for the following abstracts: 
• Abstracts #505 and #506
• Abstract #LBA504

• Abstract #1004: First analysis of SWOG S0221: A phase III trial comparing chemotherapy schedules in high risk early breast cancer. (G.T. Budd)
• Abstract #1007: A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). (J. O’Shaughnessy)
• Abstract #LBA1003: NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. (T. J. Whelan)
• Abstract #LBA1005: The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. (H.D. Bear)
• Abstract #1000: Genetic associations with taxane-induced neuropathy by genome-wide association study (GWAS) in E5103. (B. P. Schneider)
  
  Read ASCO Daily News Coverage for the following abstracts: 
• Abstract #LBA1003
• Abstract #LBA1005
• Abstract #LBA1000

• Abstract #5500: A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). (K. K. Ang)
• Abstract #5502: A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC):  Final survival analysis for the FACT trial. (J. A. Sosa)
• Abstract #5501: Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Results of the randomized phase II TREMPLIN study. (J. Lefebvre)
• Abstract #5505: Prediction of clinical outcome in patients with primary laryngeal carcinoma using gene expression profiling. (E. Fountzilas)
• Abstract #LBA5524: Phase ΙΙΙ trial of low-level laser therapy to prevent induced oral mucositis in head and neck cancer patients submitted to concurrent chemoradiation. (H. Antunes)
  
  Read ASCO Daily News Coverage for the following abstract: 
• Abstract #5500

• Abstract #4503: Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial. (B. I. Rini)
• Abstract #4516: Cabozantinib (XL184) in metastatic castration resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. (M. Hussain)
• Abstract #4512: Towards a rational strategy for prostate cancer screening based on long-term risk of prostate cancer metastases and death: Data from a large, unscreened, population-based cohort followed for up to 30 years. (H. Lilja)
• Abstract #4514: A phase III randomized trial of intermittent vs. continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG  JPR.7/CTSU JPR.7/ UK  Intercontinental Trial CRUKE/01/013). (J. M. Crook)
• Abstract #LBA4517^: Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double blind placebo controlled phase 3 study of abiraterone acetate (AA) plus low dose prednisone (P) post docetaxel. (H. I. Scher)
  
  Read ASCO Daily News Coverage for the following abstracts: 
• Abstract #4503
• Abstract #4516
• Abstract #4514
• Abstract #LBA4517^

• Daniel F. Hayes, MD, University of Michigan Medical Center 
• Harold J. Burstein, MD, PhD, Dana-Farber Cancer Institute
• Carey Anders, MD, University of North Carolina, Chapel Hill
• D. Neil Hayes, MD, MPH, University of North Carolina, Chapel Hill 
• William K. Oh, MD, Mt. Sinai School of Medicine
  
  

• Survivorship Care: Whose Job is it?
• Assessing Patients’ Psychosocial Needs: How To Do This in Your Busy Practice
• Role of Nutrition, Supplements, and Integrative Medicine in Cancer Prevention, Treatment and Survivorship 

•  Abstract #10005: Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). (S. P. Chawla)
• Abstract #LBA10002: PALETTE: A randomized double blind phase III trial of pazopanib versus placebo in patients with soft tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy. An EORTC STBSG global network study (EORTC 62072). (W. T. Van Der Graaf)
• Abstract #LBA1: Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). (H. Joensuu)
• Abstract #2: Busulphan-melphalan is the superior myeloablative therapy (MAT) for high risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial.   (R. L. Ladenstein)
  
  Read ASCO Daily News Coverage for the following abstracts:
• Abstract #10002
• Abstract #LBA1
• Abstract #2

   

• Abstract #8000: R-CHOP14 vs r-CHOP21: Result of a randomised phase III trial for the treatment of patients with newly diagnosed diffuse large b-cell non-hodgkin's lymphoma. (D. Cunningham)
• Abstract #8001: Randomized phase III US/Canadian intergroup trial (SWOG S9704) comparing CHOP±R x 8 to CHOP±R x 6 followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-hodgkin's lymphoma (NHL). (P. J. Stiff)
• Abstract #8004: Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large b-cell lymphoma (DLBCL): CORAL final analysis. (C. Gisselbrecht)
  
  Read ASCO Daily News Coverage for the following abstracts:
• Abstract #8000
• Abstract #8001

• Abstract #5003: Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). (J. A. Ledermann)
• Abstract #5001: Effect of screening on ovarian cancer mortality in the prostate, lung, colorectal and ovarian (PLCO) cancer randomized screening trial. (S. S. Buys)
• Abstract #5000: Establishing a molecular taxonomy for epithelial ovarian cancer (EOC) from 363 formalin fixed paraffin embedded (FFPE) specimens. (C. Gourley)
• Abstract #LBA5007: OCEANS: A randomized, double-blinded, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or Fallopian tube cancer (FTC). (C. Aghajanian)
  
  Read ASCO Daily News Coverage for the following abstracts:
• Abstract #5003
• Abstract #5001
• Abstract #LBA5007

• Abstract #3503: The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. (M.S. Roh)
• Abstract #3504: Capecitabine (Cape) versus 5-fluorouracil (5-FU)–based (neo-)adjuvant chemo-radiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial. (R. Hofheinz)
• Abstract #3535: Primary colorectal tumors and their metastasis are genetically not the same: Implications for choice of targeted treatment? (J. S. P. Vermaat)
• Abstract #3510^: Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first‑line metastatic colorectal cancer (mCRC). (J. Douillard)
• Abstract #3507: The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil/leucovorin (FU/L) in stage II colon cancer. (G. A. Yothers)
• Abstract #3511: Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab. (S. Tejpar)
• Abstract #10500: Comparative genomic analysis of primary versus metastasis in colorectal carcinomas. (E. Vakiani)  
  
  Read ASCO Daily News Coverage for the following abstracts: 
• Abstracts #3503 and 3504
• Abstract #3507
• Abstract #3511

• Abstract #4003: Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared to bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. (C. S. Fuchs)
• Abstract #4004: A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC). (S. H.Park)
• Abstract #LBA4002: Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the ‏Phase III CLASSIC trial. (Y.-J. Bang)
• Abstract #4005: Long-term update of U.S. GI intergroup RTOG 98-11 phase III trial for anal carcinoma: Disease-free and overall survival with RT+5FU-mitomycin versus RT+5FU-cisplatin. (L. L. Gunderson)
• Abstract #4001: Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of tts Treatment with Sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction. (J.A. Marrero)
  
  Read ASCO Daily News Coverage for the following abstracts:
• Abstract #4003
• Abstract #LBA4002
• Abstract #4005

• Abstract #8007: Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older. (A. P. Palumbo)
• Abstract #8031: Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM). (J. G. Berdeja)
• Abstract #8020: Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients : A phase III trial. (M. Boccadoro)
• Abstract #8025: Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM). (M. Wang) 
  
  

• Abstract #6500: Results of COMFORT- I, a randomized double-blind phase III trial of JAK1/2 inhibitor INCB18424 (424) vs placebo (PB) for patients with myelofibrosis (MF). (Srdan Verstovsek, MD, PhD)
• Abstract #6503^: Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial. (S.Faderl)
• Abstract #LBA6501: Results of a randomized study of the JAK inhibitor INC424 compared to best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF). (C. N. Harrison)
• Abstract #3: High dose methotrexate (HD-MTX) as compared to capizzi methotrexate plus asparaginase (C-MTX/ASNase) improves event-free survival (EFS) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL):  a report from the Children’s oncology group study AALL0232. (E. C. Larsen)
  
  Read ASCO Daily News Coverage for the following abstract: 
• Abstract #3

• Daniel F. Hayes, MD - University of Michigan Medical Center 
• Howard Hochster, MD - Yale Cancer Center
• Manesh A. Shah, MD - Memorial Sloan-Kettering Cancer Center
• Asher Alban Akmal Chanan-Khan, MD - Roswell Park Cancer Institute 
• Jane Liesveld, MD - University of Rochester

• Implementing an Electronic Health Record in Different Practice Settings: Strategies for Success
• Managing Electronic Education
• Direct to Consumer Genetic Testing: What Physicians Need to Know

• Abstract #9009: Yoga improves QOL, cortisol rhythym and HRV for women with BREAST CANCER undergoing radiotherapy. (L. Cohen)
• Abstract #LBA9014: The ultra-low-molecular-weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in cancer patients receiving chemotherapy: SAVE ONCO study. (G. Agnelli)
• Abstract #9005: Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. (E. Grunfeld)
  
• Abstract #9001: Validation of the G8 screening tool in geriatric oncology: The ONCODAGE project. (P. Soubeyran)
• Abstract #9012: A phase III study for prevention of delayed nausea: A University of Rochester CCOP study of 1,021 patients receiving chemotherapy. (G. R. Morrow)
• Abstract #9013: Phase III, double-blind, placebo-controlled, crossover study evaluating a 5HT3 antagonist with dexamethasone with or without aprepitant in patients with germ cell tumor receiving 5-day cisplatin combination chemotherapy: A Hoosier Oncology Group (HOG) study. (M. R. Brames)
  
  Read ASCO Daily News Coverage for the following abstract:
• Abstract #LBA9014

• Abstract #8509: BRIM-2: An open-label, multicenter phase II study of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. (A. Ribas)
• Abstract #8505: Randomized phase III trial of high dose interferon alfa-2b (HDI) for four weeks induction only in patients with intermediate and high-risk melanoma (Intergroup trial E 1697) . (S. S. Agarwala)
• Abstract #LBA5: A phase 3 randomized study of ipilimumab plus dacarbazine versus dacarbazine alone as first line treatment in patients with unresectable stage III or IV melanoma. (J.D. Wolchok)
• Abstract #LBA4: Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF mutated melanomas. (P. B. Chapman)
• Abstract #2006: RTOG 0525:  a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). (M. R. Gilbert)
  
  Read ASCO Daily News Coverage for the following abstracts: 
• Abstract #8505
• Abstract #LBA5
• Abstract #LBA4
• Abstract #2006

• Abstract #7004: Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer. (S. Michiels)
• Abstract #7002: Randomized phase II trial on refinement of early stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin and vinorelbine (CVb) - TREAT. (M. Kreuter)
• Abstract #7003: Proteomic analysis for detection of NSCLC: Results of ACOSOG Z4031. (D. Harpole, Jr)

• Abstract #CRA7510: PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). (L. G. Paz-Ares, MD)
• Abstract #7503: Erlotinib vs chemotherapy (CT) in advanced non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the european Tarceva vs chemotherapy (EURTAC) phase III randomized trial. (R. Rosell)
• Abstract #CRA7506: Identification of driver mutations in tumor specimens from 1000 patients with lung adenocarcinoma: The NCI’s lung cancer mutation consortium (LCMC). (M. G. Kris.)
• Abstract #7505: Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. (D. R. Spigel)
• Abstract #LBA7511: Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) in China (INFORM)  (C-TONG 0804). (L. Zhang)
• Abstract #LBA7512: Prospective biomarker analysis from MONET1, a randomized, placebo-controlled, double-blind phase 3 study of motesanib plus carboplatin/paclitaxel (C/P) in advanced nonsquamous non–small-cell lung cancer (NSCLC). (M. B. Bass)
  
  Read ASCO Daily News Coverage for the following abstracts: 
• Abstract #CRA7510
• Abstract #CRA7506
• Abstract #LBA7512